Deployment Phase Sample Clauses

Deployment Phase. Involves deployment of the Software Release; that is the software is presented to AT&T’s end users. Deployment Phase is closed when AT&T accepts this release into production. Release notes will be provided within 5 BD which define the features and any known issues -associated with the implementation. During the Inception, Elaboration and Construction phases there are 3 ongoing activities. These • Managing project issues and risks • Managing changes to requirements • Ensuring common understanding/capturing a common vocabulary AT&T change requests (submitted after the Project Plan is baselined at end of Elaboration Phase) are managed through the Motricity Change Request Process. AT&T specific features or time critical features may be implemented on top of the latest core software version by Motricity Professional Services.
Sample 1Sample 2
AutoNDA by SimpleDocs
Deployment Phase. Scientific experiments frequently encounter situations which require deviations from the original plan. It is important that all Participants be alerted to any required changes to the plan after the deployment phase has commenced. The following steps will be taken to ensure effective communications:
Sample 1
Deployment Phase. To deploy the solution, SSP will travel onsite to DME offices for ~three days. It is expected that Clevest would also be present onsite for this implementation, testing, and validation exercise. SSP will install the integration code into the client production environment. For the balance of the visit, SSP will provide onsite production support as DME users test and validate the new functionality utilizing the Clevest software against their Responder environment. Any issues will be addressed by either SSP or Clevest as needed to ensure that the integration is working as designed. DME will be expected to validate that the functionality meets the design documentation and operates correctly. Finally, upon completion of the onsite trip, SSP will provide remote support for the solution, up to 40 hours, over the following 10 business days. If support is required beyond the 10 business days or the 40 hours (whichever is achieved first) a change order may be required. At the completion of the offsite support period, the integration project will be considered complete.
Sample 1
Deployment Phase. To deploy the solution, SSP will travel onsite to DME offices for ~four days. It is expected that Trilliant and the CIS department would also be present onsite for this implementation, testing, and validation exercise. SSP will install the integration code into the client production environment. SSP will test and validate the functionality within each system as well. For the balance of the visit, SSP will provide onsite production support as DME users test and validate the new functionality. Any issues will be addressed by either SSP or Trilliant as needed to ensure that the integration is working as designed. DME will be expected to validate that the functionality meets the design documentation and operates correctly. Finally, upon completion of the onsite trip, SSP will provide remote support for the solution, up to 40 hours, over the following 10 business days. If support is required beyond the 10 business days or the 40 hours (whichever is achieved first) a change order may be required. Additional time has not been included for a second environment installation, however if this becomes a requirement, the DME SSP retainer may be utilized for the work. At the completion of the offsite support period, the integration project will be considered complete.
Sample 1
Deployment Phase. To deploy the solution, SSP will travel onsite to DME for a full week. The week will include installation and configuration of an enterprise-ready ArcGIS Online configuration including secure access of mapping services via the internet. SSP will then install and validate the NBS automation application for consuming streetlight outages entered via ArcGIS Online. SSP will also create the various web maps to be used in collecting the outages and for displaying the outage map to the public via the DME website. SSP will conclude the week by fully training DME administrative personnel on the solution, to allow them to deploy similar solutions on their own in the future. The goal is to enable DME to be as self- sufficient with the technology as possible. Finally, immediately upon conclusion of the onsite week, SSP will provide a remote support period for DME’s production usage of the application, up to five business days or 10 hours of labor, whichever occurs first. Should additional support be required, a change order may be necessary, or the DME-SSP retainer may be used.
Sample 1
Deployment Phase. Upon completion of the review, Dimension Data shall commence the deployment phase, which is expected to last no longer than two (2) months thereafter (“Deployment Phase”), Dimension Data shall deploy the Service to all Elements eligible for the Service as determined in Clause 4.2.1.1. Customer shall be liable for payment of the Service during the Deployment Phase in accordance with Schedule 1.
Sample 1
Deployment Phase 
Sample 1
AutoNDA by SimpleDocs

Related to Deployment Phase

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Launch Customer shall use commercially reasonable efforts to begin distribution of the Google Desktop Applications promptly following the launch of the Desktop Portal.

  • Commencement of Work Engineer shall not commence any field work under this Contract until he/she/it has obtained all required insurance and such insurance has been approved by County. As further set out below, Engineer shall not allow any subcontractor/subconsultant(s) to commence work to be performed in connection with this Contract until all required insurance has been obtained and approved and such approval shall not be unreasonably withheld. Approval of the insurance by County shall not relieve or decrease the liability of Engineer hereunder.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • TECHNICAL SUPPORT SERVICES 2.1 The technical support services (the "Services"): Party A agrees to provide to Party B the relevant services requested by Party B, which are specified in Exhibit 1 attached hereto ("Exhibit 1").

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

Time is Money Join Law Insider Premium to draft better contracts faster.